Grifols announced robust second-quarter 2025 results, reporting 7% revenue growth and 12.5% EBITDA growth, alongside near-record margins. These figures underscore the company's strong operational recovery and its leading position in the global plasma industry.
The company made significant progress in its deleveraging efforts, successfully reducing its leverage ratio to 4.2x. This reduction addresses a key financial priority and strengthens Grifols' balance sheet, enhancing its financial stability.
Furthermore, Grifols reinstated its dividend, signaling improved financial health and confidence in its sustained profitability and cash flow generation. This move is expected to be well-received by investors, reflecting the company's commitment to returning value to shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.